Dr. Reddy's Laboratories Limited

DRREDDY

INE089A01023

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:53 2024-07-16 EDT			5-day change	1st Jan Change
6,643 ^INR	-2.20%		+0.91%	+14.58%

07-16	Asian Equities Traded in the US as American Depositary Receipts Move Modestly Higher in Tuesday Trading	MT
07-16	Indian Equities Achieve New Closing Highs on Tuesday, Led by Realty, FMCG Goods Stocks	MT

Doctor Reddy's: Fiscal Q3 Earnings Snapshot

January 25, 2023 at 08:55 am

HYDERABAD, India (AP) _ Dr. Reddy's Laboratories Ltd. (RDY) on Wednesday reported net income of $151 million in its fiscal third quarter.

On a per-share basis, the Hyderabad, India-based company said it had net income of 91 cents.

The pharmaceutical posted revenue of $818 million in the period.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RDY at https://www.zacks.com/ap/RDY

Latest news about Dr. Reddy's Laboratories Limited

Asian Equities Traded in the US as American Depositary Receipts Move Modestly Higher in Tuesday Trading	07-16	MT
Indian Equities Achieve New Closing Highs on Tuesday, Led by Realty, FMCG Goods Stocks	07-16	MT
Jefferies Forecasts Strong Fiscal Q1 for Indian Pharmaceuticals	07-16	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading	07-15	MT
Dr. Reddy's Laboratories Limited Receives an Order from The Joint Commissioner,, Office of the Commissioner of Central Tax, Kochi Towards Tax Demand Including Interest and Penalty	07-15	CI
Asian Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading	07-10	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher in Monday Trading	07-08	MT
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	07-05	MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	07-03	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note	07-01	MT
Dr. Reddy's to Co-market Zydus' Breast Cancer Treatment in India	06-28	MT
Zydus and Dr. Reddy's Announces Licensing Agreement for Co-Marketing of Pertuzumab Biosimilar, a Critical Treatment for Breast Cancer Patients in India	06-28	CI
India plans incentives for diabetes, obesity drug makers in 2026, government official says	06-28	RE
Indian Equities Fall on Friday, Dragged Mainly by Banking Stocks	06-28	MT
Asian Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	06-27	MT
Dr. Reddy's to Acquire Haleon's Nicotine Replacement Therapy Business Outside US	06-27	MT
INDIA STOCKS-UltraTech Cement, Reliance power Indian shares to record highs	06-27	RE
Dr. Reddy's Laboratories to Acquire Nicotinell Portfolio From Haleon	06-26	MT
Haleon to Sell Nicotine-Quitting Aid Business for $634 Million -- Update	06-26	DJ
Transcript : Dr. Reddy's Laboratories Limited - Special Call	06-26
Haleon to Sell Nicotine-Quitting Aid Business for $634 Million	06-26	DJ
Haleon to sell nicotine replacement therapy business outside US for $633 mln	06-26	RE
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading	06-25	MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	06-24	MT
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	06-21	MT

Chart Dr. Reddy's Laboratories Limited

Duration

Period

More charts

Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows: - sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines; - sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services; - other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc. Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).

Sector

Pharmaceuticals

Calendar

2024-07-26 - Q1 2025 Earnings Release

Related indices

NIFTY 50 , NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Dr. Reddy's Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

6,643 INR

Average target price

6,164 INR

Spread / Average Target

-7.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DR. REDDY'S LABORATORIES LIMITED	+14.58%	13.54B
ELI LILLY AND COMPANY	+61.53%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.66%	359B
MERCK & CO., INC.	+15.06%	325B
ABBVIE INC.	+9.18%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.67%	177B
PFIZER, INC.	+2.47%	165B

Other Pharmaceuticals

Dr. Reddy's Laboratories Limited

Equities

DRREDDY

INE089A01023

Pharmaceuticals

Doctor Reddy's: Fiscal Q3 Earnings Snapshot

EPS Revisions